← brief for 2026-08-19 · Slowing decline

Dapagliflozin vs. Standard Care for the Prevention of Atrial Fibrillation Early Recurrence After Catheter Ablation in Patients With Persistent Atrial Fibrillation: Rationale and Design of the DARE-AF Trial

Paper A Peer reviewed Meta-analysis or large trial

Key takeaways

Dapagliflozin may reduce risk of atrial fibrillation recurrence in patients with CKD. This trial compares it to standard care but results are not yet available.

Who did this work

Zejun Yang (Capital Medical University) · Zixu Zhao (Capital Medical University) · Chao Jiang (Capital Medical University) · Yang Xu (Capital Medical University) · Hui Xu (Capital Medical University) · Hang Guo (Capital Medical University) · Yiping Wang (Capital Medical University) · Mingxiao Li (Capital Medical University) · Le Zhou (Capital Medical University) · Liu He (Capital Medical University) · Chenxi Jiang (Capital Medical University) · Ribo Tang (Capital Medical University)

Source

Paper · OpenAlex, CKD works · 2026-08-18
https://doi.org/10.1097/cd9.0000000000000204